| Literature DB >> 35005527 |
Karthik Ramachandran1, Soumya Maity1, Alagar R Muthukumar2, Soundarya Kandala1, Dhanendra Tomar3, Tarek Mohamed Abd El-Aziz4,5, Cristel Allen1, Yuyang Sun6, Manigandan Venkatesan1, Travis R Madaris1, Kevin Chiem7, Rachel Truitt8, Neelanjan Vishnu1, Gregory Aune9, Allen Anderson1, Luis Martinez7, Wenli Yang8, James D Stockand3, Brij B Singh6, Subramanya Srikantan1, W Brian Reeves1, Muniswamy Madesh1.
Abstract
SARS-CoV-2 is a newly identified coronavirus that causes the respiratory disease called coronavirus disease 2019 (COVID-19). With an urgent need for therapeutics, we lack a full understanding of the molecular basis of SARS-CoV-2-induced cellular damage and disease progression. Here, we conducted transcriptomic analysis of human PBMCs, identified significant changes in mitochondrial, ion channel, and protein quality-control gene products. SARS-CoV-2 proteins selectively target cellular organelle compartments, including the endoplasmic reticulum and mitochondria. M-protein, NSP6, ORF3A, ORF9C, and ORF10 bind to mitochondrial PTP complex components cyclophilin D, SPG-7, ANT, ATP synthase, and a previously undescribed CCDC58 (coiled-coil domain containing protein 58). Knockdown of CCDC58 or mPTP blocker cyclosporin A pretreatment enhances mitochondrial Ca2+ retention capacity and bioenergetics. SARS-CoV-2 infection exacerbates cardiomyocyte autophagy and promotes cell death that was suppressed by cyclosporin A treatment. Our findings reveal that SARS-CoV-2 viral proteins suppress cardiomyocyte mitochondrial function that disrupts cardiomyocyte Ca2+ cycling and cell viability.Entities:
Keywords: Cardiovascular medicine; Transcriptomics; Virology
Year: 2022 PMID: 35005527 PMCID: PMC8720045 DOI: 10.1016/j.isci.2021.103722
Source DB: PubMed Journal: iScience ISSN: 2589-0042
Figure 1Transcriptome profiling reveals robust perturbation of mitochondrial energetics components during COVID-19 progression
(A) Heatmap of all RNA transcripts in PBMCs from healthy SARS-CoV-2-negative volunteers (n = 2), symptomatic (n = 3), and severely affected COVID-19 patients (n = 2).
(B) PCA plot of normalized FPKM of RNA-seq from seven samples.
(C) Unsupervised hierarchical cluster analysis of COVID-19 patient transcripts.
(D) List of enriched transcript categories differentially expressed in COVID-19 patients.
(E) Venn diagram represents three major categories of gene ontology.
(F) Patient characteristics and blood test results.
Figure 2SARS-CoV-2 infection and its proteins targeting promote mitochondrial fragmentation in human iPSC-cardiomyocytes
(A) Representative confocal images of Ad mitoGCaMP6 as a mitochondrial marker in iPSC-CMs before or after 24 h of SARS-CoV-2 infection. SARS-CoV-2 MOI 1. Bar graphs depict the analysis of mitochondrial shape parameters.
(B) Representative confocal images of MitoTracker Red as a mitochondrial marker in iPSC-CMs before or after 24 h of SARS-CoV-2 infection. SARS-CoV-2 MOI 1. Bar graphs depict the analysis of mitochondrial shape parameters.
(A and B) Data are presented as the mean ± SEM, n = 5 independent experiments. ∗∗p <0.01, ∗∗∗p <0.01, ∗∗∗∗p <0.0001.
(C) Ectopic expression of individual SARS-CoV-2 proteins in COS-7 Cells.
(D-H) Individual viral proteins were transiently transfected in COS-7 cells to visualize the intracellular localization of viral proteins tagged with mRFP (red) on a single-cell basis. Representative confocal images of live cells stained with ER (ER Tracker, blue) and mitochondrial markers (DHR123, green). Spatial overlap and intensity profiles demonstrate ER and mitochondrial localization of viral proteins.
(H) Table depicts subcellular localization of thirteen SARS-CoV-2 proteins.
(I) Analysis of mitochondrial phenotypes (length and area) in cells expressing SARS-CoV-2 proteins. Data are presented as mean ± SEM, n = 3–6 independent experiments. ∗∗∗∗p <0.0001.
Figure 3Severely affected COVID-19 PBMCs exhibited an elevation of mitochondrial resident CCDC58 candidate
(A-B) Heatmap and plot of mitochondrial perturbation subpopulations from groups I, II, and III human subjects.
(C) Assessment of CCDC58 cellular localization. HeLa cells were transiently cotransfected with FLAG-tagged CCDC58 and mitochondrial marker Cox-8A-mRFP plasmid constructs. Immunofluorescence analysis of CCDC58 localization shows the mitochondrial localization.
(D) Spatial overlap and intensity profiles demonstrate mitochondrial colocalization of CCDC58 and COX8A mitochondrial targeting polypeptide.
(E) Representative traces of Ca2+ uptake in NegshRNA or CCDC58 KD HEK293 cells.
(F) CCDC58 mRNA expression in NegshRNA or CCDC58 shRNA HEK293 cells. Mean ± SEM. n = 3.
(G) Representative traces of Ca2+ uptake in HEK293T cells expressing Neg shRNA, NegshRNA + M-Protein, CCDC58 KD, or CCDC58 KD + M-Protein.
(H) Calcium retention capacity in HEK293T cells quantified as the number of Ca2+ (10 μM) pulses taken up. Data presented as mean ± SEM. n = 3. ∗p <0.05 ∗∗∗p <0.001
Figure 4SARS-CoV-2 proteins interact with mitochondrial PTP complex
(A) COS-7 cells were cotransfected with HA-tagged PPIF and FLAG-tagged SARS-CoV-2 protein plasmid constructs. Following immunoprecipitation with HA antibody, total cell lysates and immunoprecipitated materials were subjected to western blot analysis. Cell lysates were probed with anti-FLAG or anti-HA antibodies. Immunoprecipitated samples were probed with anti-FLAG (top right) and anti-HA antibodies (bottom right). n = 3.
(B) Western blot analysis of cell lysates (left) or immunoprecipitates (right) from COS-7 cells coexpressing HA-tagged SPG7 and FLAG-tagged SARS-CoV-2 protein plasmid constructs. n = 3.
(C) Western blot analysis of cell lysates (left) or immunoprecipitates (right) from COS-7 cells coexpressing Myc-tagged CCDC58 and FLAG-tagged SARS-CoV-2 protein plasmid constructs. n = 3.
(D) Western blots of cell lysates or immunoprecipitated material from COS-7 cells transiently coexpressing PPIF, SPG7, or CCDC58 proteins. Cells were lysed, immunoprecipitated with Myc antibody, and immunoblotted for HA. n = 3.
(E) SARS-CoV-2 proteins and Mitochondrial PTP Complex binding. COS-7 cells were transfected with FLAG-tagged SARS-CoV-2 protein plasmid constructs. Following immunoprecipitation with FLAG antibody, SPG7, ANT, and ATP synthase interactions were assessed by western blot using specific antibodies.
(F) Scheme depicts protein-protein interaction of mitochondrial PTP complex with SARS-CoV-2 proteins.
Figure 5SARS-CoV-2 infection exacerbates autophagy in human iPSC-cardiomyocytes
(A) Heatmap depicts the enrichment of cellular and mitochondrial quality control transcripts in severely affected COVID-19 patients.
(B and C) Effect of SARS-CoV-2 on cardiomyocytes cyto-skeletal and ER architecture. Representative confocal images of Tubulin-GFP and ER marker (Sec61b-mCherry) expressing iPSC-CMs before or after 24 h of SARS-CoV-2 infection. A multiplicity of infection (MOI) of 1 was used for SARS-CoV-2 in Ad5-tfLC3 (mRFP-GFP tandem fluorescent-tagged LC3, tfLC2, adenovirus)-infected iPSC-CMs.
(D) Representative confocal images of mRFP-GFP tfLC3 in iPSC-CMs before or after 24 h of SARS-CoV-2 infection. SARS-CoV-2 MOI 1.
(E) Quantification of autophagy was performed as normalized LC3 puncta. Data are presented as the mean ± SEM, n = 3–4 independent experiments. ∗p <0.05.
Figure 6mPTP complex blocker cyclosporin A restores mitochondrial bioenergetics cardiomyocyte viability from SARS-CoV-2-induced damage
(A) Mitochondrial oxygen consumption rate (OCR) of vector or SARS-CoV-2 stably expressing COS-7 cells. Bar graph depicts basal, maximal, and proton leak. Mean ± SEM. n = 3–4. The p values were determined by one-way ANOVA with Tukey's test. Data are presented as the mean ± SEM, n = 3–4 independent experiments. ∗p <0.05, ∗∗∗∗p <0001. n.s., not significant.
(B) The traces represent extracellular acidification rate and these data are derived from (A)
(C-D) Representative traces of number of Ca2+ pulses cleared by mitochondria (CRC). Vector or SARS-CoV-2 M-protein stably expressing HEK293 cells were permeabilized and exposed to boluses of 10 μM Ca2+ pulses with (C) or without (D) cyclosporin A (1 μM) at the indicated time point.
(E) Quantification of mitochondrial CRC in both control and viral protein expressing conditions. Data are presented as the mean ± SEM, n = 3–6 independent experiments. ∗p <0.05, ∗∗p <0.01, ∗∗∗p <001. n.s., not significant.
(F) Assessment of cardiomyocyte viability following SARS-CoV-2 infection. hiPSC-cardiomyocytes were challenged with virus at an MOI of 1 for 24 h. After viral infections, cells were subjected to MTT assay to determine the viability. Data are presented as the mean ± SEM, n = 4–8 independent experiments. ∗∗p <0.01, n.s., not significant.
Figure 7SARS-CoV-2 proteins suppress LTCC channel activity in cardiomyocytes
(A) Schematic overview of the study. Twenty days after the start of differentiation, hiPSC-CMs were exposed to SARS-CoV-2 virus (1 MOI) for 24 h before RNA isolation to perform RNA-seq analysis.
(B) PCA plot of normalized FPKM of RNA-seq from control (n = 3) and SARS-CoV-2-infected hiPSC-CMs (n = 3).
(C) Cluster analysis of control and SARS-CoV-2 infected hiPSC-CMs.
(D) Targeted ion channel transcripts differentially modulated in hiPSC-CMs upon SARS-CoV-2 infection (n = 3).
(E) Representative optical recordings show Fluo-4 Ca2+ cycling traces in both control (RFP-tagged plasmid) and RFP-tagged SARS-CoV-2 M-protein or NSP-6 overexpressing hiPSC-CMs.
(F) Quantification of Ca2+ oscillations frequency in cardiomyocytes. These data are derived from traces in A. Data are presented as the mean + SEM, n = 3–4 independent experiments.
(G) Current-voltage relationship of CaV1.2 channels in control and viral protein-overexpressing hiPSC-CMs.
(H) Peak current densities (pA) for control or SARS-CoV-2 expressing hiPSC-CMs. n = 6–12. Data are presented as the mean ± SEM, n = 4–10 independent experiments. ∗∗∗∗p <0.0001.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Monoclonal ANTI-FLAG® M2 | Sigma Aldrich, MO, USA | Cat# F3165 |
| Flag, Rabbit monoclonal antibody | Cell Signaling Technology, MA, USA | Cat# 14793 |
| Myc-Tag (71D10) Rabbit monoclonal antibody | Cell Signaling Technology | Cat# 2278S |
| β-Actin (C4) | Santa Cruz Biotechnology, TX, USA | Cat# SC47778 |
| HA-Tag Rabbit monoclonal antibody | Cell Signaling Technology, MA, USA | Cat#3724S |
| Goat Anti-Rat IgG (H+L) Secondary Antibody, Biotin | Invitrogen, NY, USA | Cat# 31830 |
| Anti-ATP5G1 | Invitrogen, NY, USA | Cat# PA5-68102 |
| Anti-SPG7 | Invitrogen, NY, USA | Cat# PA5-87106 |
| Anti-ANT (H-188) | Santa Cruz Biotechnology, TX, USA | Cat# SC- 11433 |
| Mouse Anti-Rabbit IgG Conformation Specific (L27A9) mAb (HRP) | Cell Signaling Technology, MA, USA | Cat# 5127S |
| Anti-Cyclophilin F antibody | abcam, MA, USA | Cat# ab110324 |
| Anti-Tom20 | abcam, MA, USA | Cat# ab56783 |
| Anti-Cytochrome c | Santa Cruz Biotechnology, TX, USA | Cat# sc13156 |
| Monoclonal anti-ATP5A | abcam, MA, USA | Cat# ab14748 |
| SARS-CoV-2 | Texas BioMed Research Institute (San Antonio, Texas) | |
| Ad-h-Sec61-mCherry | Vector BioLabs | ADV-222504 |
| Ad-Tubulin GFP | Vector BioLabs | ADV-226814 |
| Ad-mito-GCamp6m | ||
| Lenti-ccdc58 shRNA | Sigma/Aldrich | |
| Halt™ Protease and Phosphatase Inhibitor Cocktail | ThermoFisher Scientific, NY, USA | Cat# 78441 |
| NuPAGE™ LDS Sample Buffer (4X) | ThermoFisher Scientific | Cat# NP0007 |
| Restore™ PLUS Western Blot Stripping Buffer | ThermoFisher Scientific | Cat# 46430 |
| Pierce™ 20X TBS Tween™ 20 Buffer | ThermoFisher Scientific | Cat# 28360 |
| MES SDS Running Buffer (20X) | ThermoFisher Scientific | Cat# B0002 |
| SuperSignal™ West Pico PLUS Chemiluminescent Substrate | ThermoFisher Scientific | Cat# 34578 |
| Bis-Tris Polyacrylamide Gel | ThermoFisher Scientific | Cat# WG1402BOX |
| BoltTM LDS sample buffer (4X) | ThermoFisher Scientific | Cat# B0007 |
| RIPA Buffer | Abcam, MA, USA | Cat# 156034 |
| Pierce IP Lysis buffer | ThermoFisher Scientific | Cat# 87788 |
| Non-fat dry skimmed milk | Lab Scientific, MA, USA | Cat# M-0841 |
| Dihydrorhodamine 123 (DHR 123) | ThermoFisher Scientific | Cat# D23806 |
| FURA-FF Pentapotassium Salt | Cayman Chemical, MI, USA | Cat# 20415 |
| JC-1 | ThermoFisher Scientific | Cat# 65-0851-38 |
| MitoSOXTM Red | ThermoFisher Scientific | Cat# M3008 |
| FCCP | Sigma Aldrich, MO, USA | Cat# C2920 |
| Tetramethylrhodamine, Ethyl Ester, Perchlorate (TMRE) | ThermoFisher Scientific | Cat# T669 |
| Ionomycin from | Sigma Aldrich, MO, USA | Cat# I9657 |
| Thapsigargin | Thermo Fisher Scientific | Cat# T7458 |
| Digitonin | Sigma Aldrich, MO, USA | Cat# D141 |
| Thiazovivin | Cayman Chemical, MI, USA | Cat# 14245 |
| Gelatin | MilliporeSigma, MA, USA | Cat# ES-006B |
| Calcium Chloride | Sigma Aldrich, MO, USA | Cat# 2115 |
| Glucose | Sigma Aldrich, MO, USA | Cat# G8644 |
| Sodium Succinate | Sigma Aldrich, MO, USA | Cat# S2378 |
| DMSO | Sigma Aldrich, MO, USA | Cat# D8418 |
| Fetal Bovine Serum, Characterized, Heat Inactivated | Hyclone (GE Life Sciences) | Cat#SH30396.03 |
| DPBS Ca2+/Mg2+ Free | Gibco (ThermoFisher Scientific) | Cat#14190 |
| Collagen 1 Rat Tail | Gibco (ThermoFisher Scientific) | Cat#A10483 |
| Sodium Pyruvate, 100mM | Gibco (ThermoFisher Scientific) | Cat# 11360 |
| Hanks' Balanced Salt Solution, Ca2+/Mg2+ Free | Gibco (ThermoFisher Scientific) | Cat# 14175 |
| HEPES (1M) | Gibco (ThermoFisher Scientific) | Cat# 15630 |
| EGTA, OmniPur (powder) | MilliporeSigma, MA, USA | Cat# 4100-50GM |
| B-27 Supplement | Gibco (ThermoFisher Scientific) | Cat#17504-044 |
| MEM – Non-Essential Amino Acids, 100X | Gibco (ThermoFisher Scientific) | Cat# 11140 |
| Antibiotic-Antimycotic, 100X | Gibco (ThermoFisher Scientific) | Cat# 15240 |
| L-Glutamine, 200mM | Gibco (ThermoFisher Scientific) | Cat# 250030 |
| Mito Tracker Deep red FM | Invitrogen, ThermoFischer Scientific, USA | Cat# M22426 |
| Neutral buffered Formalin | Cole Parmer, ThermScientific IL, USA | Cat# 5701 |
| DMEM High glucose | Hyclone, Cytiva, MA, USA | Cat# SH30243.01 |
| RPMI Medium | Hyclone, Cytiva, MA, USA | Cat# SH30027.01 |
| Seahorse XF DMEM Medium | Agilent, USA | Cat# 103575-100 |
| Trypsin 0.05% | Gibco (ThermoFisher Scientific) | Cat# 25200-056 |
| Trypsin 0.25% | Gibco (ThermoFisher Scientific) | Cat# 25300-054 |
| Adenosine Triphosphate Mg2+ salt | Sigma Aldrich, MO, USA | Cat# A9187 |
| Pierce Anti-c-Myc magnetic Beads | ThermoFischer Scientific, USA | Cat# 88842 |
| Pierce Anti-HA magnetic Beads | ThermoFischer Scientific, USA | Cat# 88836 |
| Β-mercaptoethanol | ThermoFischer Scientific, USA | BP176-100 |
| FLAG HA Tandem Affinity Purification Kiet | Sigma Aldrich, MO, USA | Cat# Tp0010 |
| Precision Plus Protein dual color standards | BIORAD, CA, USA | Cat#1610374 |
| Tetrodotoxin Citrate | TOCRIS, MN, USA | Cat#1069 |
| Nifedipine | Sigma Aldrich, MO, USA | Cat# N7634 |
| Cesium chloride | Sigma Aldrich, MO, USA | Cat# C4036 |
| Pierce™ BCA Protein Assay Kit | ThermoFisher Scientific | Cat# 23225 |
| RNeasy Plus Universal Mini Kit | QIAGEN, MD, USA | Cat# 73404 |
| Agilent Seahorse XF Cell Mito Stress Test Kit | Agilent Technologies, CA, USA | Cat# 103015-100 |
| Agilent Seahorse XFe96 FluxPak | Agilent Technologies | Cat# 102416-100 |
| CellTiter 96 Non-radioactive cell proliferation assay | Promega, USA | Cat# G4002 |
| Cell Titer-Glo Luminescence Kit | Promega, USA | Cat# G7570 |
| iBlot PVDF Regular Stacks | Invitrogen, ThermoFischer Scientific, USA | Cat# IB24001 |
| NEB Next Ultra RNA Library Prep Kit for Illumina | New England Biolabs, MA, USA | Cat# E7530L |
| FuGENE 6 Transfection Reagent | Promega, USA | Cat# E2691 |
| Human: HEK293 Cells | ATCC | Cat# CRL-1573 |
| Human: HEK293T Cells | ATCC | Cat# CRL-3216 |
| ATCC | Cat# CRL-1651 | |
| Human HeLa Cervical cancer cells | ATCC | Cat# CCL-2 |
| Human: PBMC Primary Cells | UT Southwestern, TX, USA | N/A |
| Human: iPSC-derived Cardiomyocytes (PENN123i-SV20) | N/A | |
| pVector-RFP | OriGene, MD, USA | |
| pM Protein-RFP | OriGene, MD, USA | |
| pOrf9c-RFP | OriGene, MD, USA | |
| pOrf3a-RFP | OriGene, MD, USA | |
| pNsp6-RFP | OriGene, MD, USA | |
| pNsp7-RFP | OriGene, MD, USA | |
| pOrf10-RFP | OriGene, MD, USA | |
| pOrf9b-RFP | OriGene, MD, USA | |
| pNsp5-RFP | OriGene, MD, USA | |
| pNsp14-RFP | OriGene, MD, USA | |
| pNsp8-RFP | OriGene, MD, USA | |
| pNsp9-RFP | OriGene, MD, USA | |
| pNsp10-RFP | OriGene, MD, USA | |
| pNsp4-RFP | OriGene, MD, USA | |
| pGCamp6-mt | N/A | |
| pCox-8 A mRFP | OriGene, MD, USA | RC100126 |
| GraphPad Prism version 8 | GraphPad Software | v8.0 |
| Canvas 11.0 | ACD Systems | v11.0 |
| Agilent Seahorse Wave Desktop Software 2.6.1 | Agilent Technologies, CA, USA | |
| Leica Application Suite X (LAS X) | Leica Microsystems Inc., IL, USA | |
| Agilent Seahorse Wave | Agilent Technologies, CA, USA | Wave 2.6.1 |
| Microsoft Office | Microsoft Corporation, WA, USA | 2013/2016 |
| Felix GX Software | PTI, Horiba, Canada | Felix Gx, Version 4 |
| Zen 2010 | Carl Zeiss Inc, Ob, Germany | Zeiss, LM510 |
| Zen Blue | Carl Zeiss Inc, Ob, Germany | Zeiss LSM 10 META |
| R | v3.6.2 | |
| DESeq2 (R Package) | ||
| Bcl2fastq | Illumina, CA, USA | v2.17 |
| Illustration Toolkit- Pathway | Motifolio, MD, USA | |
| Image J | ||